Prostate cancer - The Lancet
ASCO GU 2022: Overall Survival after Progression on First Novel Hormonal Therapy in Patients with Metastatic Castration-Sensitive Versus Castration-Resistant Prostate Cancer (mCSPC Versus mCRPC)
ESMO Virtual Congress 2020: The Final Overall Survival Analysis of the PROfound Study: Olaparib vs Physician's Choice of Enzalutamide or Abiraterone in Patients with mCRPC and Homologous Recombination Repair Gene Alteration
Efficacy I PLUVICTO
Progression-free survival of mCRPC patients treated with AAP | Download Scientific Diagram
Real-World Treatment Patterns and Overall Survival of Patients with Metastatic Castration-Resistant Prostate Cancer in the US Prior to PARP Inhibitors | SpringerLink
Impact of new systemic therapies on overall survival of patients with metastatic castration-resistant prostate cancer in a hospital-based registry | Prostate Cancer and Prostatic Diseases
Overall Survival in mCRPC Cases Linked to Number of Radium-223 Doses - Renal and Urology News
Median overall survival (in months) for patients who did not receive... | Download Scientific Diagram
Impact of new systemic therapies on overall survival of patients with metastatic castration-resistant prostate cancer in a hospital-based registry.,Prostate Cancer and Prostatic Diseases - X-MOL
Overall survival. mCRPC metastatic castration-resistant protate cancer.... | Download Scientific Diagram
Real World Patterns of PSA Response and Survival with Abiraterone and Enzalutamide in Metastatic Castrate Resistant Prostate Cancer (mCRPC) | Clinical Oncology and Research | Science Repository | Open Access
Five-year Survival Prediction and Safety Outcomes with Enzalutamide in Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer from the PREVAIL Trial - ScienceDirect
Overall Survival Data in mCRPC
Survival outcomes in patients with chemotherapy-naive metastatic castration-resistant prostate cancer treated with enzalutamide or abiraterone acetate | Prostate Cancer and Prostatic Diseases
Cytoreductive radiotherapy combined with abiraterone in metastatic castration-resistance prostate cancer: a single center experience | Radiation Oncology | Full Text
A-C) Overall survival of 68 patients with metastesis castration... | Download Scientific Diagram
a) Progression free and b) overall survival probability of patients... | Download Scientific Diagram
Overall survival of black and white men with metastatic castration-resistant prostate cancer (mCRPC): a 20-year retrospective analysis in the largest healthcare trust in England | Prostate Cancer and Prostatic Diseases
Optimal sequencing of commonly used medications for treatment of metastatic castration-resistant prostate cancer - Mayo Clinic
Understanding what matters to metastatic castration‐resistant prostate cancer (mCRPC) patients when considering treatment options: A US patient preference survey - George - Cancer Medicine - Wiley Online Library
Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer | NEJM
The Effect of Treatment Sequence on Overall Survival for Men With Metastatic Castration-resistant Prostate Cancer: A Multicenter Retrospective Study - ScienceDirect
mCRPC: PREVAIL Trial | HCP Site | XTANDI® (enzalutamide)
Docetaxel Rechallenge Improves Survival in Patients With Metastatic Castration-resistant Prostate Cancer: A Retrospective Study | In Vivo
